



## Personalized Medicine in Skull Base and Sinonasal Tumors

Guest Editors:

**Dr. Davide Mattavelli**

Unit of Otorhinolaryngology—  
Head and Neck Surgery,  
Department of Medical and  
Surgical Specialties, Radiological  
Sciences and Public Health, ASST  
Spedali Civili of Brescia,  
University of Brescia, Brescia,  
Italy

**Dr. Paolo Bossi**

Unit of Medical Oncology,  
Department of Medical and  
Surgical Specialties, Radiological  
Sciences and Public Health, ASST  
Spedali Civili of Brescia,  
University of Brescia, Brescia,  
Italy

Deadline for manuscript  
submissions:

**closed (5 March 2024)**

### Message from the Guest Editors

In recent decades, multidisciplinary approaches and innovations in treatments (such as endoscopic surgery and heavy ion irradiation) have improved outcomes in sinonasal and skull base tumors. However, a relevant proportion of patients still bears a poor prognosis despite the intensified regimen of treatment. Tumor biology largely drives prognosis in this subset of patients, while the rarity of these tumors, together with their great histologic variety, hinders a more accurate definition of tumor profiles. Multi-omics analysis could largely improve our understanding of these diseases and provide us with biomarkers to better depict these tumors at multiple levels: diagnosis, prognostic stratification, and the prediction of response to treatment. Likewise, they can identify therapeutic targets to inspire new pharmaceutical options. In this regard, the tumor–host interplay, immune contexture, and immunotherapy are still to be investigated in sinonasal and skull base tumors, representing a new therapeutic frontier to explore.

Overall, such studies can possibly pave the way towards a more effective, less toxic, personalized therapy.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)